Last deal

$6.5M

Amount

Series C

Stage

28.09.2010

Date

3

all rounds

$32.49M

Total amount

date founded

Financing round

General

About Company
Tigris Pharmaceuticals develops therapeutic technologies for oncology and other medical needs.

Industry

Sector :

Subsector :

founded date

01.01.2005

Number of employees

Company Type

For Profit

Last funding type

Series C

IPO status

Private

Description

Tigris Pharmaceuticals is a biopharmaceutical company based in Bonita Springs, Florida. They focus on developing and commercializing biopharmaceutical products for the treatment of cancer and infectious diseases. Their product portfolio includes Aminoflavone, GGTI-2418, and GFB-204, which are used to treat various types of cancer. The company is currently conducting a Phase II clinical study for A-007, a topical treatment for pre-cancerous and cancerous anogenital lesions associated with HPV. Tigris Pharmaceuticals also seeks to acquire global rights to additional product candidates in oncology and infectious diseases to address unmet medical needs.
Contacts
Similar Companies
1000
Sunesis Pharmaceuticals

Sunesis Pharmaceuticals

Sunsen Pharmaceuticals is developing new oncology therapeutics for the treatment of solid and hematologic cancers.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Pharmaceuticals

Location

South San Francisco, CA, USA

total rounds

10

total raised

$234.3M
Karyopharm Therapeutics

Karyopharm Therapeutics

Karyopharm Therapeutics is a clinical-stage pharmaceutical company developing drugs for cancer and other major diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Pharmaceuticals, Health Care

Location

Newton, MA, USA

total rounds

8

total raised

$546.7M
Akeso Biopharma

Akeso Biopharma

Akeso Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for oncology and immunology.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Zhong Shan Jie, An Hui Sheng, China

total rounds

4

total raised

$219.97M
Antengene Corporation

Antengene Corporation

Antengene is a global biopharmaceutical company focused on developing innovative oncology therapies.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Shanghai, China

total rounds

4

total raised

$238M

Financials

Funding Rounds
3
3

Number of Funding Rounds

$32.49M

Money Raised

Their latest funding was raised on 28.09.2010. Their latest investor NGN Capital. Their latest round Series C

Date 
Funding Round 
Investors 
Money Raised 
Lead 
28.09.2010
2
$6.5M
30.09.2005
$9.99M
NGN Capital

NGN Capital

NGN Capital is a New York-based venture capital firm that specializes in healthcare investments in the US and Europe.

Sector

Open End and Miscellaneous Investment Vehicles

Subsector

Open End and Miscellaneous Investment Vehicles

Location

New York, NY, USA

count Of Investments

32

count Of Exists

11
Wexford Capital

Wexford Capital

Wexford Capital manages hedge and private equity funds, boasting $6.5 billion of assets under management.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Financial Services, Venture Capital, Finance

Location

Greenwich, CT, USA

count Of Investments

25

count Of Exists

8
Co-Investors
Investors
4
2

Number of lead investors

4

Number of investors

Investor 
Lead 
Round 
Partners 
Yes
Series B
Yes
Series B
NGN Capital

NGN Capital

NGN Capital is a New York-based venture capital firm that specializes in healthcare investments in the US and Europe.

Sector

Open End and Miscellaneous Investment Vehicles

Subsector

Open End and Miscellaneous Investment Vehicles

Location

New York, NY, USA

count Of Investments

32

count Of Exists

11
Wexford Capital

Wexford Capital

Wexford Capital manages hedge and private equity funds, boasting $6.5 billion of assets under management.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Financial Services, Venture Capital, Finance

Location

Greenwich, CT, USA

count Of Investments

25

count Of Exists

8
Sonostar Capital Partners

Sonostar Capital Partners

Sonostar Capital Partners, LLC pools investment capital to pursue entrepreneurial opportunities.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Financial Services, Venture Capital, Finance

Location

Chappaqua, NY, USA

count Of Investments

2

People

Founders
1
Mark Pruzanski
Mark Pruzanski

Mark Pruzanski

Mark Pruzanski is the Chairman and Chief Executive Officer of Versanis Bio. He previously worked at National Geographic as an International Council of Advisors. Mark Pruzanski attended The Johns Hopkins University - Paul H. Nitze School of Advanced International Studies (SAIS).

current job

Versanis Bio
Versanis Bio

Mark Pruzanski

Employee Profiles
3

Anne White

COO

Mark Pruzanski

Mark Pruzanski

Founder

Edmundo Muniz

President & CEO

Activity

Recent News
0